ARTICLE | Clinical News

Aristada aripiprazole lauroxil regulatory update

October 12, 2015 7:00 AM UTC

FDA approved Aristada aripiprazole lauroxil from Alkermes to treat schizophrenia. The company plans to launch the injectable, extended-release formulation of aripiprazole using LinkeRx technology “immediately.” Alkermes said the product is the first atypical antipsychotic with both once-monthly and 6-week dosing options (see BioCentury, July 20 & Sept. 7). ...